Trial reportHuman gene therapy2003
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
Trial report in Human gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 108 citations in OpenAlex.
- Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.Cancer immunology, immunotherapy : CII · 2010Trial
- Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.Cancer immunology, immunotherapy : CII · 2005Trial
- A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.British journal of cancer · 2004Trial
- Suitable Promoter for DNA Vaccination Using a pDNA Ternary Complex.Pharmaceutics · 2024Article
- Preclinical and clinical development of DNA vaccines for prostate cancer.Urologic oncology · 2016Review
- Cancer vaccines.BMJ (Clinical research ed.) · 2015Review
- DNA vaccines, electroporation and their applications in cancer treatment.Human vaccines & immunotherapeutics · 2015Review
- Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.Journal of cancer research and clinical oncology · 2014Article
- Article
- Trial watch: DNA vaccines for cancer therapy.Oncoimmunology · 2013Article
- Article
- The role of peptide and DNA vaccines in myeloid leukemia immunotherapy.Cancer cell international · 2013Article
- Article
- Functional VEGF haplotypes affect the susceptibility to hypertension.Journal of human hypertension · 2013Article
- Article
- Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine.Systems and synthetic biology · 2011Article
- Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.Archivum immunologiae et therapiae experimentalis · 2010Review
- TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy.Journal of biomedicine & biotechnology · 2010Review
- DNA vaccines: developing new strategies against cancer.Journal of biomedicine & biotechnology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
Immunization with plasmid DNA represents a theoretically attractive method for increasing T cell responses against cancer antigens. We administered plasmid DNA encoding the gp100 melanoma-melanocyte differentiation antigen to 22 patients with metastatic melanoma and evaluated immunologic and clinical responses. Patients were randomized to receive plasmid DNA either intradermally (n = 10) or intramuscularly (n = 12). One patient (4.5%) exhibited a partial response of several subcentimeter cutaneous nodules. All other patients had progressive disease. Of 13 patients with cells available before and after immunization, no patient exhibited evidence of the development of anti-gp100 cell responses using in vitro boost assays. The same assays were capable of demonstrating immunologic precursors after immunization with fowl poxvirus encoding gp100 or with gp100 peptides. We were thus unable to demonstrate significant clinical or immunologic responses to plasmid DNA encoding the "self" nonmutated gp100 tumor antigen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.